Abstract

For FY14, the Integrated Research Facility in the Division of Clinical Research has significantly increased the level of research facilitation that it provides. Primarily, this support has been directed to facilitating the biodefense and emerging infectious disease research of the Emerging Viral Pathogens section in the Division of Intramural Research, reported separately. In addition, core capabilities of the IRF have been established to include clinical pathology, anatomic pathology, electron microscopy, confocal microscopy, immunology, and cell culture. Rodents were introduced into the facility in November 2012, followed by primates in December of the same year. Medical imaging using all four modalities on uninfected animals was initiated in January 2013 followed by infections of non-Select Agents in March 2013. Aerosol infectivity studies began in April 2013, followed by influenza and MERS in July 2013. Research involving Ebola virus including West African strains was initiated in August 2014.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Clinical Support Services Intramural Research (ZID)
Project #
1ZIDAI009006-06
Application #
8946625
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost

  Institution

Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Bramble, Matthew S; Hoff, Nicole; Gilchuk, Pavlo et al. (2018) Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors. J Infect Dis 218:1929-1936
Luke, Thomas; Bennett, Richard S; Gerhardt, Dawn M et al. (2018) Fully Human Immunoglobulin G From Transchromosomic Bovines Treats Nonhuman Primates Infected With Ebola Virus Makona Isolate. J Infect Dis :
Davey Jr, Richard T; Dodd, Lori; Proschan, Michael et al. (2018) The Past Need Not Be Prologue: Recommendations for Testing and Positioning the Most-Promising Medical Countermeasures for the Next Outbreak of Ebola Virus Infection. J Infect Dis :
Iwasaki, Masaharu; Minder, Petra; Caì, Yíngyún et al. (2018) Interactome analysis of the lymphocytic choriomeningitis virus nucleoprotein in infected cells reveals ATPase Na+/K+ transporting subunit Alpha 1 and prohibitin as host-cell factors involved in the life cycle of mammarenaviruses. PLoS Pathog 14:e1006892
Bodas, Manish; Mazur, Steven; Min, Taehong et al. (2018) Inhibition of histone-deacetylase activity rescues inflammatory cystic fibrosis lung disease by modulating innate and adaptive immune responses. Respir Res 19:2
Cooper, Timothy K; Sword, Jennifer; Johnson, Joshua C et al. (2018) New Insights Into Marburg Virus Disease Pathogenesis in the Rhesus Macaque Model. J Infect Dis :
Cline, John Mark; Dugan, Greg; Bourland, John Daniel et al. (2018) Post-Irradiation Treatment with a Superoxide Dismutase Mimic, MnTnHex-2-PyP5+, Mitigates Radiation Injury in the Lungs of Non-Human Primates after Whole-Thorax Exposure to Ionizing Radiation. Antioxidants (Basel) 7:
Logue, James; Tuznik, Kaylie; Follmann, Dean et al. (2018) Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. J Virol Methods 255:84-90
Rimoin, Anne W; Lu, Kai; Bramble, Matthew S et al. (2018) Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection. J Infect Dis 217:223-231
Smith, Darci R; Johnston, Sara C; Piper, Ashley et al. (2018) Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl Trop Dis 12:e0006474

Showing the most recent 10 out of 85 publications